# Safety, PK, and PD of BSA204 in Chinese Adults With Borderline Elevated Lipoprotein(a)

> **NCT07551505** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Bisirna Therapeutics (Suzhou) Co., Ltd.** · enrollment: 40 (estimated)

## Conditions studied

- Dyslipidemias

## Interventions

- **DRUG:** BSA204
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07551505
- **Lead sponsor:** Bisirna Therapeutics (Suzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-20
- **Primary completion:** 2027-07-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07551505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07551505, "Safety, PK, and PD of BSA204 in Chinese Adults With Borderline Elevated Lipoprotein(a)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07551505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*